GlassScriptPhysician profile
Jason A Badillo
NPI 1396770202
$1,442.79
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $258 · 2022: $310 · 2023: $722 · 2024: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $207.79 | 2021-2023 | Camzyos, Eliquis |
| Cvrx, INC. | $146.19 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $145.30 | 2023-2024 | Brilinta, Lokelma |
| Novartis Pharmaceuticals Corporation | $129.77 | 2022-2024 | |
| Lexicon Pharmaceuticals, INC. | $120.57 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $90.71 | 2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $75.41 | 2021 | |
| Boston Scientific Corporation | $73.37 | 2021 | |
| Novo Nordisk INC | $73.01 | 2022-2024 | Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.40 | 2023 | Lifevest |
| Pfizer INC. | $54.08 | 2021-2023 | |
| Amgen INC. | $51.45 | 2023-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.64 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $41.37 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $23.03 | 2023 | Nexletol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $21.62 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $20.35 | 2023 | Evkeeza |
| Philips North America LLC | $19.67 | 2023 | |
| Irhythm Technologies, INC. | $18.77 | 2022 | |
| Astellas Pharma US INC | $14.57 | 2022 | |
| Atricure, INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Badillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.